ARMAGEN TECHNOLOGIES INC has a total of 34 patent applications. Its first patent ever was published in 2005. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, PARDRIDGE WILLIAM M and ROCHE GLYCART AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | United States | 7 | |
#3 | Australia | 5 | |
#4 | Canada | 5 | |
#5 | EPO (European Patent Office) | 4 | |
#6 | Japan | 3 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes | |
#5 | Microorganisms | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Pardridge William M | 30 |
#2 | Boado Ruben J | 30 |
#3 | William M Pardridge | 3 |
#4 | Ruben J Boado | 3 |
#5 | Boado Ruben | 1 |
#6 | Pardridge William | 1 |
Publication | Filing date | Title |
---|---|---|
AU2016202625A1 | Methods and compositions for increasing alpha-iduronidase activity in the CNS | |
WO2015009961A1 | Compositions and methods related to structures that cross the blood brain barrier | |
AU2013206657A1 | Methods and compositions for increasing alpha-iduronidase activity in the CNS | |
CA2857647A1 | Methods and compositions for increasing arylsulfatase a activity in the cns | |
WO2009070597A2 | Fusion proteins for delivery of gdnf to the cns | |
AU2008282496A1 | Methods and compositions for increasing alpha-iduronidase activity in the CNS | |
CA2661042A1 | Agents for blood-brain barrier delivery |